Organon & Co..
pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 58
What's happening
Earlier this month
-
Organon & Co. and CASI Pharmaceuticals, Inc. are being compared as healthcare companies.Some support1 report
-
Organon & Co. and Sun Pharmaceutical Industries reported on recent acquisition proposals and strong growth in their India formulations business.Some support2 reports
-
MarketBeat provided analyst recommendations and compared Organon & Co. and Xeris Biopharma.Some support1 report
One to three months ago
Gone quiet
No new reports in 90+ days-
State Street Corp and Vanguard Group Inc. increased their holdings in Organon & Co. on August 7, 2026.Some support1 report
-
Organon & Co. gained exclusive commercialization rights for the drug Pyzchiva.Some support1 report
-
Organon & Co. is headquartered in Jersey City, New Jersey, and uses LinkedIn for communication.Some support1 report
-
Recursion Pharmaceuticals and Organon & Co. both reported positive Earnings ESP on July 22, 2025.Some support1 report
-
Trump pledged to unleash American oil and gas production involving Organon & Co.Some support2 reports
-
Several healthcare companies, including Kadant and Hims & Hers Health, reported significant market-beating returns over five years.Speculative1 report
-
Analyst inquiries to Organon & Co. management covered competition risk, share repurchases, and sales targets.Speculative1 report
-
The American Academy of Dermatology recommended Organon & Co.'s cream for the management of Atopic Dermatitis.Some support2 reports
-
Juan Camilo Arjona Ferreira was appointed CMO at Organon & Co. in July 2025.Some support2 reports
-
Both Medpace and Organon & Co. are being considered for investment in the Medical Services sector.Some support2 reports
-
Organon acquired U.S. rights to TOFIDENCE from Biogen and laid off employees at its Jersey City headquarters.Some support1 report
-
Zacks.com tracked Organon & Co.'s stock performance on July 23, 2025.Some support2 reports
-
Kevin Ali was appointed as the CEO of Organon & Co. on August 7, 2025.Some support1 report
-
Investors consider AI stocks for greater upside potential, involving Organon & Co.Some support1 report
-
Organon shares returned -8.2% on August 12, 2025, while the Zacks Medical Services industry lost 2.5%.Some support2 reports
-
Planned Parenthood issues are causing market hesitancy, with Matthew Walsh providing a financial outlook.Some support1 report
-
Nexplanon and Organon & Co. are facing market headwinds in Europe, including the loss of exclusivity for Atozet and questioning the impact of potential EU tariffs on 2026 margins.Some support1 report
-
Robert Bruce made various stock transactions in LyondellBasell, Vicor Corp, The Chemours Co, and Organon & Co. on August 15, 2025.Some support1 report
-
A podcast discussed thermal management systems for energy reduction, innovations in materials like cement and steel, and transforming buildings and transport.Some support2 reports
-
FDA recognized Hadlima as an interchangeable biosimilar for Humira, supporting Organon's biosimilars pipeline.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Organon & Co. this week
News at the entities that move Organon & Co. most-
MarketBeat Mentioned togetherMarketBeat used its stock screener tool to highlight Walmart.Moves Organon & Co.
-
Trane Technologies OperationalTrane Technologies granted funding to Goodwill-Easter Seals Minnesota.Moves Organon & Co.
-
SEC StructuralMSCI index rules may affect Bitcoin companies, while warnings caused stock market crashes in Turkey and Indonesia.Moves Organon & Co.
-
Korea Shared contextTourism benefits in Korea are expanding geographically beyond the capital city of Seoul.Moves Organon & Co.
-
China Shared contextJim Townsend addressed NATO policies, the rise of China, and Russia's invasion of Ukraine during a presentation.Moves Organon & Co.
-
Europe Shared contextWar was raging across Europe in 1941.Moves Organon & Co.
Connections
The 9 strongest of 58, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Sun Pharmaceutical Transactional
Sun Pharmaceutical has proposed an $11.75 billion acquisition bid for Organon & Co.
-
Juan Camilo Arjona Ferreira Structural
Juan Camilo Arjona Ferreira holds the role of CMO and Head of R&D at Organon & Co.
-
SEC Structural
Organon & Co. must comply with SEC regulations by filing information regarding institutional holdings.
-
Natera Operational
Both medical companies are noted to be competing for investment capital.
-
Trane Technologies Operational
Both companies are active in the thermal management systems market, with evidence suggesting a supply relationship.
-
MarketBeat Mentioned together
MarketBeat provides analyst recommendations and coverage for Organon & Co.
-
Korea Shared context
Organon & Co. operates in markets that include Korea.
-
Europe Shared context
Organon & Co. operates within the European market, particularly concerning biosimilars and exclusivity.
Show all 9 connections
-
China Shared context
Organon & Co. operates within the markets of China.
History
Events by the month they beganOctober 2026
3 events- Organon & Co. and CASI Pharmaceuticals, Inc. are being compared as healthcare companies.
- Organon & Co. and Sun Pharmaceutical Industries reported on recent acquisition proposals and strong growth in their India formulations business.
- MarketBeat provided analyst recommendations and compared Organon & Co. and Xeris Biopharma.
September 2026
2 eventsAugust 2026
1 eventShow 1 earlier month
June 2026
19 events- Organon & Co. gained exclusive commercialization rights for the drug Pyzchiva.
- Organon & Co. is headquartered in Jersey City, New Jersey, and uses LinkedIn for communication.
- Recursion Pharmaceuticals and Organon & Co. both reported positive Earnings ESP on July 22, 2025.
- Trump pledged to unleash American oil and gas production involving Organon & Co.
- Several healthcare companies, including Kadant and Hims & Hers Health, reported significant market-beating returns over five years.
- Analyst inquiries to Organon & Co. management covered competition risk, share repurchases, and sales targets.
- The American Academy of Dermatology recommended Organon & Co.'s cream for the management of Atopic Dermatitis.
- Juan Camilo Arjona Ferreira was appointed CMO at Organon & Co. in July 2025.
- Both Medpace and Organon & Co. are being considered for investment in the Medical Services sector.
- Organon acquired U.S. rights to TOFIDENCE from Biogen and laid off employees at its Jersey City headquarters.
- Zacks.com tracked Organon & Co.'s stock performance on July 23, 2025.
- Kevin Ali was appointed as the CEO of Organon & Co. on August 7, 2025.
- Investors consider AI stocks for greater upside potential, involving Organon & Co.
- Organon shares returned -8.2% on August 12, 2025, while the Zacks Medical Services industry lost 2.5%.
- Planned Parenthood issues are causing market hesitancy, with Matthew Walsh providing a financial outlook.
- Nexplanon and Organon & Co. are facing market headwinds in Europe, including the loss of exclusivity for Atozet and questioning the impact of potential EU tariffs on 2026 margins.
- Robert Bruce made various stock transactions in LyondellBasell, Vicor Corp, The Chemours Co, and Organon & Co. on August 15, 2025.
- A podcast discussed thermal management systems for energy reduction, innovations in materials like cement and steel, and transforming buildings and transport.
- FDA recognized Hadlima as an interchangeable biosimilar for Humira, supporting Organon's biosimilars pipeline.